Measuring treatment adverse event burden in myasthenia gravis : Single-center prospective evaluation utilizing the Adverse Event Unit (AEU)
© 2023 The Authors. Muscle & Nerve published by Wiley Periodicals LLC..
INTRODUCTION/AIMS: We developed a patient- and physician-weighted consensus unit called the adverse event unit (AEU) that quantifies and compares adverse event (AE) burden among any group of medications in neurological patients. In this study we evaluated preliminary validity and feasibility of measuring AE burden with the AEU in myasthenia gravis (MG).
METHODS: This is a single-center, prospective, 1-year, observational study of adult MG patients presenting for routine care between April 1, 2021 and March 31, 2022. The MG Activities of Daily Living (MG-ADL), the 15-item MG Quality of Life revised (MG-QOL15r), MG-Composite, and AEU scores were obtained at all visits. A priori primary feasibility metric was AEU completion rate equal to (within 3.8%, one-sided 95% confidence interval [CI]) or better than MG-ADL completion rate. Time to administer AEU and MG-ADL/MG-QOL15r, correlation between AEU total score and MG-QOL15r, and median AEU scores for each MG medication were evaluated.
RESULTS: Fifty-four patients completed 67 study visits; side effects were reported at 75% of the visits. The study met the primary feasibility endpoint; AEU and MG-ADL were recorded at all visits. Times to administer the AEU (median 5 minutes) and MG-ADL/MG-QOL15r were similar. We observed a weak correlation of 0.29 (95% CI 0.03 to 0.51, P = .032) between AEU and MG-QOL15r scores. Non-statistically significant differences in median AEU scores were observed among MG medications.
DISCUSSION: Our data demonstrate preliminary feasibility and validity of using the AEU to measure AE burden in MG. Future studies will compare AE burden among MG treatments and evaluate clinically meaningful AEU scores in MG.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Muscle & nerve - 69(2023), 1 vom: 07. Jan., Seite 32-39 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hehir, Michael K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse events |
|---|
| Anmerkungen: |
Date Completed 27.12.2023 Date Revised 27.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/mus.27966 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361737572 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361737572 | ||
| 003 | DE-627 | ||
| 005 | 20231229123854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/mus.27966 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1240.xml |
| 035 | |a (DE-627)NLM361737572 | ||
| 035 | |a (NLM)37676119 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hehir, Michael K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Measuring treatment adverse event burden in myasthenia gravis |b Single-center prospective evaluation utilizing the Adverse Event Unit (AEU) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2023 | ||
| 500 | |a Date Revised 27.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Muscle & Nerve published by Wiley Periodicals LLC. | ||
| 520 | |a INTRODUCTION/AIMS: We developed a patient- and physician-weighted consensus unit called the adverse event unit (AEU) that quantifies and compares adverse event (AE) burden among any group of medications in neurological patients. In this study we evaluated preliminary validity and feasibility of measuring AE burden with the AEU in myasthenia gravis (MG) | ||
| 520 | |a METHODS: This is a single-center, prospective, 1-year, observational study of adult MG patients presenting for routine care between April 1, 2021 and March 31, 2022. The MG Activities of Daily Living (MG-ADL), the 15-item MG Quality of Life revised (MG-QOL15r), MG-Composite, and AEU scores were obtained at all visits. A priori primary feasibility metric was AEU completion rate equal to (within 3.8%, one-sided 95% confidence interval [CI]) or better than MG-ADL completion rate. Time to administer AEU and MG-ADL/MG-QOL15r, correlation between AEU total score and MG-QOL15r, and median AEU scores for each MG medication were evaluated | ||
| 520 | |a RESULTS: Fifty-four patients completed 67 study visits; side effects were reported at 75% of the visits. The study met the primary feasibility endpoint; AEU and MG-ADL were recorded at all visits. Times to administer the AEU (median 5 minutes) and MG-ADL/MG-QOL15r were similar. We observed a weak correlation of 0.29 (95% CI 0.03 to 0.51, P = .032) between AEU and MG-QOL15r scores. Non-statistically significant differences in median AEU scores were observed among MG medications | ||
| 520 | |a DISCUSSION: Our data demonstrate preliminary feasibility and validity of using the AEU to measure AE burden in MG. Future studies will compare AE burden among MG treatments and evaluate clinically meaningful AEU scores in MG | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adverse events | |
| 650 | 4 | |a complications | |
| 650 | 4 | |a drug therapy | |
| 650 | 4 | |a immunosuppressive agents | |
| 650 | 4 | |a myasthenia gravis | |
| 650 | 4 | |a side effects | |
| 650 | 4 | |a therapeutics | |
| 700 | 1 | |a Conaway, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a St Sauveur, Avery B |e verfasserin |4 aut | |
| 700 | 1 | |a Feb, Kendall |e verfasserin |4 aut | |
| 700 | 1 | |a Kolb, Noah A |e verfasserin |4 aut | |
| 700 | 1 | |a Waheed, Waqar |e verfasserin |4 aut | |
| 700 | 1 | |a McNeish, Brendan L |e verfasserin |4 aut | |
| 700 | 1 | |a Tweedy, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Burns, Ted M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Muscle & nerve |d 1985 |g 69(2023), 1 vom: 07. Jan., Seite 32-39 |w (DE-627)NLM000369063 |x 1097-4598 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2023 |g number:1 |g day:07 |g month:01 |g pages:32-39 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/mus.27966 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2023 |e 1 |b 07 |c 01 |h 32-39 | ||